Product Description: Olanzapine-d8 is a deuterated labeled Olanzapine[1]. Olanzapine (LY170053) is a selective, orally active monoaminergic antagonist with high affinity binding to serotonin H1, 5HT2A/2C, 5HT3, 5HT6 (Ki=7, 4, 11, 57, and 5 nM, respectively), dopamine D1-4 (Ki=11 to 31 nM), muscarinic M1-5 (Ki=1.9-25 nM), and adrenergic α1 receptor (Ki=19 nM). Olanzapine is an atypical antipsychotic[2][3].
Formula: C17H12D8N4S
References: [1]Vucicevic L, et al. Autophagy inhibition uncovers the neurotoxic action of the antipsychotic drug olanzapine. Autophagy. 2014;10(12):2362-78./[2]APPROVED AGREED-UPON LABELING./[3]Karpel-Massler G, et al. Olanzapine inhibits proliferation, migration and anchorage-independent growth in human glioblastoma cell lines and enhances temozolomide's antiproliferative effect. J Neurooncol. 2015 Mar;122(1):21-33./[4]Olanzapine for Injection, powder, for solution for intramuscular use./[5]Coccurello R, et al. Chronic administration of olanzapine induces metabolic and food intake alterations: a mousemodel of the atypical antipsychotic-associated adverse effects. Psychopharmacology (Berl). 2006 Jul;186(4):561-71./[6]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216.
CAS Number: 1093380-13-2
Molecular Weight: 320.48
Research Area: Neurological Disease
Target: 5-HT Receptor;Adrenergic Receptor;Apoptosis;Autophagy;Dopamine Receptor;Isotope-Labeled Compounds;mAChR;Mitophagy
English
Deutsch
